Opsidio, LLC, a US-based clinical stage biotechnology company, announced on Wednesday that it has dosed its first subject in the Phase 2a clinical trial of OpSCF, the company's pioneering monoclonal antibody against stem cell factor, in subjects suffering from moderate to severe atopic dermatitis.
The company is collaborating with AbbVie for the development of OpSCF.
The study, a randomised, double-blind, placebo-controlled, Phase 2a study, is to assess the efficacy and safety of OpSCF in the treatment of adults with moderate to severe atopic dermatitis. The primary endpoint is the percent change in the Eczema Area and Severity Index (EASI) score from baseline, at week 16, while the secondary endpoint comprises safety and tolerability and improvement in pruritus, body surface area, and quality of life.
Myosin Therapeutics' MT-125 granted US FDA Fast Track designation in glioblastoma
Boehringer Ingelheim's JASCAYD (nerandomilast) IPF treatment gains Chinese regulatory approval
ACM Biolabs reports ACM-CpG Phase 1 study findings in tumour treatment
Galera Therapeutics sells dismutase mimetics portfolio to Biossil in USD108.5m agreement
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi's efdoralprin alfa shows superior results in phase 2 study for AATD
Genflow Biosciences publishes second European patent application for SIRT6 Variant in NASH
Trellus Health signs contract with leading global CRO and expands clinical trial offerings
GSK reports positive Phase III data for low-carbon version of Ventolin inhaler
Terns Pharmaceuticals reports topline 12-week data from Phase 2 trial of TERN-601 in obesity
The Los Angeles Trust for Children's Health Appoints Dr Sarah Rodman as New Executive Director
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio